DCN and neoplasm: IL-12 also seems to have great potential as adjuvant for tumor therapy especially in combination with other substances like doxorubicin (DOX), decorin (DOC) or oncolytic adenovirus expressing suicide genes, resulting in better anti-tumor immune response as shown in murine colorectal cancer, prostate cancer or 4T1 orthotopic breast cancer models (Oh et al., 2017[146]; Hu et al., 2014[82]; Ahn et al., 2016[4]; Freytag et al., 2013[53]).